Bone sarcomas, especially osteosarcoma and Ewing sarcoma, are primary bone tumors mainly affecting children and young adults. Current treatment did not progress for the last 40 years and, is based on a multimodal therapy including neo-adjuvant chemotherapy, surgical resection, and radiotherapy in some cases. With these therapeutic options, the survival rate reaches 60-70% for the localized forms but drastically drops down to 25-30% for the bad responders to treatment or for patients with metastasis at the diagnosis. The unsatisfactory outcomes and side effects associated with the current chemotherapy underscore the urgent need to find new therapeutic approaches for osteosarcoma and Ewing sarcoma. In this context, a better knowledge of bone biology has become essential for the medical and cancer research communities. This article collection aims to provide the most recent data on primary bone cancers development including genomic and proteomic analyses, clinical analyses, as well as future directions for new therapies and clinical trials for these pediatric tumors.
Potential topics include:
• Epigenomic, genomic and proteomic analysis in the development of primary bone tumors
• Cellular and molecular mechanisms underlying primary bone tumors
• Clinical analysis (histopathology and imaging) in primary bone tumors
• Importance of bone microenvironment (bone cells, immune cells…) to support development and progression of primary bone tumors
• Resistance to treatment and future horizons in treatments of primary bone tumors
We welcome contributions of different types of articles including original research articles, hypotheses, and theory, as well as reviews and mini-reviews.
Bone sarcomas, especially osteosarcoma and Ewing sarcoma, are primary bone tumors mainly affecting children and young adults. Current treatment did not progress for the last 40 years and, is based on a multimodal therapy including neo-adjuvant chemotherapy, surgical resection, and radiotherapy in some cases. With these therapeutic options, the survival rate reaches 60-70% for the localized forms but drastically drops down to 25-30% for the bad responders to treatment or for patients with metastasis at the diagnosis. The unsatisfactory outcomes and side effects associated with the current chemotherapy underscore the urgent need to find new therapeutic approaches for osteosarcoma and Ewing sarcoma. In this context, a better knowledge of bone biology has become essential for the medical and cancer research communities. This article collection aims to provide the most recent data on primary bone cancers development including genomic and proteomic analyses, clinical analyses, as well as future directions for new therapies and clinical trials for these pediatric tumors.
Potential topics include:
• Epigenomic, genomic and proteomic analysis in the development of primary bone tumors
• Cellular and molecular mechanisms underlying primary bone tumors
• Clinical analysis (histopathology and imaging) in primary bone tumors
• Importance of bone microenvironment (bone cells, immune cells…) to support development and progression of primary bone tumors
• Resistance to treatment and future horizons in treatments of primary bone tumors
We welcome contributions of different types of articles including original research articles, hypotheses, and theory, as well as reviews and mini-reviews.